Achillion Pharmaceuticals, Inc. (ACHN) Reaches $3.67 After 3.00% Up Move; Intact Financial (TSE:IFC) Had 3 Analysts Last Week

May 18, 2018 - By Orlando Nugent

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Logo

The stock of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) is a huge mover today! The stock increased 2.09% or $0.075 during the last trading session, reaching $3.665. About 626,713 shares traded. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) has declined 2.57% since May 18, 2017 and is downtrending. It has underperformed by 14.12% the S&P500.The move comes after 6 months positive chart setup for the $507.02 million company. It was reported on May, 18 by Barchart.com. We have $3.77 PT which if reached, will make NASDAQ:ACHN worth $15.21 million more.

Among 8 analysts covering Intact Financial Corporation (TSE:IFC), 3 have Buy rating, 0 Sell and 5 Hold. Therefore 38% are positive. Intact Financial Corporation had 32 analyst reports since July 22, 2015 according to SRatingsIntel. The stock has “Outperform” rating by RBC Capital Markets on Thursday, November 3. RBC Capital Markets downgraded the shares of IFC in report on Monday, January 9 to “Sector Perform” rating. The rating was downgraded by IBC to “Neutral” on Friday, October 27. The firm earned “Sector Outperform” rating on Wednesday, July 22 by Scotia Capital. The stock has “Outperform” rating by Raymond James on Friday, October 20. The firm has “Hold” rating given on Wednesday, February 1 by Desjardins Securities. The stock has “Market Perform” rating by Keefe Bruyette & Woods on Thursday, April 6. The rating was maintained by TD Securities on Friday, January 27 with “Hold”. The stock of Intact Financial Corporation (TSE:IFC) earned “Outperform” rating by Scotia Capital on Friday, April 7. Cormark Securities downgraded the stock to “Market Perform” rating in Friday, July 31 report. See Intact Financial Corporation (TSE:IFC) latest ratings:

Investors sentiment increased to 2.08 in 2017 Q4. Its up 1.12, from 0.96 in 2017Q3. It increased, as 10 investors sold Achillion Pharmaceuticals, Inc. shares while 28 reduced holdings. 34 funds opened positions while 45 raised stakes. 110.36 million shares or 4.96% more from 105.14 million shares in 2017Q3 were reported. South Dakota Council invested 0.05% of its portfolio in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). Da Davidson holds 0.01% or 114,612 shares. Fincl Bank Of America Corp De stated it has 0% in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). Dekabank Deutsche Girozentrale stated it has 69,800 shares or 0% of all its holdings. Cubist Systematic Strategies Limited Liability Co stated it has 0% of its portfolio in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). State Street Corp reported 0% stake. California State Teachers Retirement System holds 0% or 184,465 shares in its portfolio. Geode Capital Mngmt Ltd holds 0% of its portfolio in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) for 1.05M shares. Proshare Lc owns 91,640 shares or 0% of their US portfolio. Integral Derivatives Ltd Company reported 15,368 shares. Cornerstone Mngmt Limited Company invested in 97,088 shares or 0% of the stock. Grp Incorporated One Trading Lp has invested 0% in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). British Columbia – Canada-based Connor Clark Lunn Invest Mgmt Ltd has invested 0% in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). Susquehanna Intl Gru Ltd Liability Partnership has invested 0% of its portfolio in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). Voya Investment Mngmt Limited Liability holds 55,819 shares or 0% of its portfolio.

More recent Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) news were published by: Globenewswire.com which released: “Achillion Reports First Quarter 2018 Financial Results and Management Transition” on May 02, 2018. Also Globenewswire.com published the news titled: “Achillion Announces Upcoming Scientific Presentations at the 55th ERA-EDTA Congress” on May 11, 2018. Globenewswire.com‘s news article titled: “Achillion to Present at the Deutsche Bank 43rd Annual Health Care Conference” with publication date: May 04, 2018 was also an interesting one.

Analysts await Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) to report earnings on August, 14. They expect $-0.13 earnings per share, up 18.75% or $0.03 from last year’s $-0.16 per share. After $-0.15 actual earnings per share reported by Achillion Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -13.33% EPS growth.

Among 11 analysts covering Achillion Pharma (NASDAQ:ACHN), 6 have Buy rating, 0 Sell and 5 Hold. Therefore 55% are positive. Achillion Pharma had 27 analyst reports since August 13, 2015 according to SRatingsIntel. Leerink Swann maintained the shares of ACHN in report on Wednesday, May 4 with “Market Perform” rating. The stock of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) earned “Neutral” rating by Chardan Capital Markets on Friday, November 4. Robert W. Baird maintained it with “Hold” rating and $4.0 target in Monday, September 11 report. The stock has “Outperform” rating by Leerink Swann on Thursday, May 18. The rating was maintained by Robert W. Baird on Monday, October 23 with “Hold”. The stock of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) earned “Buy” rating by Maxim Group on Thursday, February 25. The firm has “Buy” rating by UBS given on Tuesday, September 8. The company was maintained on Wednesday, August 9 by Chardan Capital Markets. As per Thursday, July 7, the company rating was upgraded by JMP Securities. The stock of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) earned “Buy” rating by Maxim Group on Wednesday, August 9.

Achillion Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for infectious diseases and immune system disorders in the United States and internationally. The company has market cap of $507.02 million. The Company’s drug candidates for treating chronic hepatitis C virus infection comprise Odalasvir, a NS5A inhibitor, which has completed Phase IIa clinical trials; ACH-3422, a NS5B nucleotide polymerase inhibitor; and Sovaprevir, a NS3 protease inhibitor that has completed Phase II clinical trial. It currently has negative earnings. The firm is also developing ACH-4471, a complement factor D inhibitor, which is in Phase I clinical trial to treat patients with paroxysmal nocturnal hemoglobinuria and C3G, a disease resulting from alternative pathway over-activation; and other factor D inhibitors.

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: